Simvastatin
Ximve contains the active substance simvastatin. Ximve is a medicine used to reduce the level of cholesterol in the blood, "bad" cholesterol (LDL cholesterol) and fatty substances called triglycerides. Additionally, Ximve increases the level of "good" cholesterol (HDL cholesterol). Ximve belongs to a group of medicines called statins.
Cholesterol is one of several fatty substances present in the blood. Total cholesterol mainly consists of LDL cholesterol and HDL cholesterol.
LDL cholesterol is often referred to as "bad" cholesterol because it can accumulate on the walls of arteries, forming plaques. Eventually, these plaques can cause narrowing of the arteries, resulting in restricted or blocked blood flow to vital organs, such as the heart and brain. Restricted blood flow can lead to a heart attack or stroke.
HDL cholesterol is often referred to as "good" cholesterol because it helps prevent the accumulation of bad cholesterol in the arteries and protects against heart disease.
Triglycerides are another type of fat present in the blood, which can contribute to an increased risk of developing heart disease.
While taking this medicine, you should follow a cholesterol-reducing diet.
Ximve is used as a supplement to a cholesterol-reducing diet, in the case of:
In most people, there are no direct symptoms of high cholesterol levels. The doctor may assess the cholesterol level by ordering a simple blood test. You should regularly attend check-ups, monitor your cholesterol level, and discuss your treatment goals with your doctor.
If you are unsure whether you are taking any of the above medicines, consult your doctor.
Before starting treatment with Ximve, you should discuss it with your doctor or pharmacist.
You should inform your doctor:
gravis (a disease that causes muscle weakness, including eye muscles), as statins can sometimes exacerbate symptoms of the disease or lead to the development of myasthenia (see section 4).
Your doctor should perform a blood test before starting treatment with Ximve and during treatment if you have any liver disorders. The purpose of the test is to assess liver function.
Your doctor may also perform blood tests to assess liver function after starting treatment with Ximve.
During therapy, your doctor will closely monitor your health if you have diabetes or are at risk of developing diabetes. The risk of developing diabetes exists in people who have high levels of sugar and fats in the blood, are overweight, and have high blood pressure.
You should inform your doctor about any serious lung diseases.
The risk of muscle damage is higher when taking higher doses of Ximve, particularly the 80 mg dose. The risk of muscle breakdown is also higher in some patients. You should tell your doctor if:
You should also inform your doctor or pharmacist if you experience persistent muscle weakness. To diagnose and treat this condition, additional tests and medications may be necessary.
The safety and efficacy of simvastatin have been studied in boys aged 10-17 years and girls who have started menstruation (menstruation) at least one year earlier (see section 3 "How to take Ximve"). Simvastatin has not been studied in children under the age of 10. For more information, consult your doctor.
You should tell your doctor about all medicines you are currently taking or plan to take, including those that are available without a prescription. If it is necessary to take fusidic acid orally to treat a bacterial infection, it may be necessary to temporarily stop taking Ximve. Your doctor will inform you when it is safe to restart taking Ximve.
Grapefruit juice contains one or more compounds that affect the action of some medicines in the body, including Ximve. You should avoid drinking grapefruit juice.
Do not take Ximve if you are pregnant, planning to have a child, or think you may be pregnant. If you become pregnant while taking Ximve, you should stop treatment and consult your doctor immediately. Do not take Ximve while breastfeeding, as it is not known whether the medicine is excreted in breast milk.
Before taking any medicine, consult your doctor or pharmacist.
Ximve does not affect the ability to drive or use machines. However, you should consider that some people may experience dizziness after taking Ximve.
Ximve tablets contain a sugar called lactose. If you have been diagnosed with intolerance to some sugars, consult your doctor before taking Ximve.
Your doctor will determine the dose of Ximve suitable for you, depending on your current treatment and individual risk.
This medicine should always be taken as directed by your doctor. If you are unsure, consult your doctor or pharmacist.
While taking Ximve, you should follow a cholesterol-reducing diet.
Dosage:
The recommended dose is 10 mg, 20 mg, 40 mg, or 80 mg taken orally once a day.
Adults:
The initial dose is 10 mg, 20 mg, or in some cases 40 mg per day. Your doctor may adjust the dose after at least 4 weeks of treatment to a maximum of 80 mg per day. Do not take more than 80 mg per day.
Your doctor may recommend lower doses, especially if you are taking certain medicines listed above or have certain kidney problems.
For children (aged 10-17 years), the recommended initial dose is 10 mg once daily in the evening.
The maximum recommended dose is 40 mg per day.
Method of administration:
Ximve should be taken in the evening. The medicine can be taken with or without food. Ximve should be taken continuously until your doctor advises you to stop.
If your doctor has prescribed Ximve with another cholesterol-lowering medicine containing a bile acid sequestrant, take Ximve at least 2 hours before or 4 hours after taking the bile acid sequestrant.
Consult your doctor or pharmacist.
Do not take a double dose to make up for a missed dose. Take the next dose of Ximve at the usual time the next day.
Consult your doctor or pharmacist, as your cholesterol level may increase again.
If you have any further doubts about taking this medicine, consult your doctor or pharmacist.
Like all medicines, Ximve can cause side effects, although not everybody gets them.
The following terms are used to describe how often side effects are reported:
The following rare but serious side effects have been reported:
The following very rare but serious side effects have been reported:
The following side effects have also been reported, but their frequency is not known:
Additional possible side effects reported during the use of some statins:
Laboratory test results
Elevated muscle enzyme activity (creatine kinase) in the blood and abnormal liver function test results have been observed.
If you experience any side effects, including those not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not take this medicine after the expiry date stated on the carton/blisters after "EXP". The expiry date refers to the last day of the month.
Store in a temperature below 25°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Ximve is a white, oval, biconvex film-coated tablet with a score line on one side.
Ximve 10 mg - the tablets are marked with "SVT" on the side without the score line and "10" on the other side.
Ximve 20 mg - the tablets are marked with "SVT" on the side without the score line and "20" on the other side.
Ximve 40 mg - the tablets are marked with "SVT" on the side without the score line and "40" on the other side.
The tablets are packaged in blisters contained in a carton. The cartons contain 28 or 30 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorization holder:
Recordati Polska sp. z o.o.
al. Armii Ludowej 26
00-609 Warsaw
Tel. +48 22 206 84 50
Manufacturer:
Synthon Hispania S.L.
Castelló 1
08830 Sant Boi de Llobregat
Spain
Rottendorf Pharma GmbH
Ostenfelder Strasse 51-61
59320 Ennigerloh
Germany
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.